Through interviews with 17 IT practitioners experienced in NSoT deployment and use, EMA delivers practical guidance and an action plan for success LAFAYETTE, Colo., Dec. 9, 2025 /PRNewswire/ -- ...

Discover why Ventas, Inc. is gaining investor attention with strong momentum and bullish signals. Click for this look at VTR ...

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase ...

S&P 500 outlook targets a 9% gain from trend strength, tech leadership, lower rates, Fed liquidity. Read why risks and EMA ...

The revised EU pharmaceutical policy maintains eight-year data protection but reduces market protection to one year, ...

Tron (TRX) trades above $0.2800 at press time on Monday, hovering below the 50-day Exponential Moving Average (EMA) at ...

Theriva Biologics stock rose on Monday as it received positive Scientific Advice from CHMP for a Phase 3 trial of VCN-01 for ...

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01 ...

While everyone agrees on the ethical imperative to reduce animal use, the challenge of widespread readiness will depend on partnership, proof, and continued development activities. Public perception ...

EMA provided overall agreement with the proposed Phase 3 clinical trial of VCN-01 in combination with gemcitabine/nab-paclitaxel for the first-line treatment of metastatic PDAC, including sample size ...

The Save Monavale Vlei Campaign has welcomed the formal appeal lodged against the Environmental Management Agency’s (EMA) ...

Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET -- -- First and only approved option: YARTEMLEA(R) is the only approved treatment for hematopoietic stem cell ...